Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Clinical Research and Equipment Industry Analysis

UpdatedSep 25, 2025
DataAggregated Company Financials
Companies63
  • 7D-2.2%
  • 3M3.9%
  • 1Y-22.3%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.2%, driven by Thermo Fisher Scientific declining 2.3%. The industry has fallen 23% in the last year. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 25 Sep 2025US$564.6bUS$144.3bUS$14.6b30.1x38.8x3.9x
Sat, 23 Aug 2025US$573.7bUS$144.1bUS$14.5b29.6x39.6x4x
Mon, 21 Jul 2025US$520.4bUS$142.9bUS$9.1b34.3x57x3.6x
Wed, 18 Jun 2025US$531.1bUS$142.9bUS$9.2b35.4x57.9x3.7x
Fri, 16 May 2025US$505.8bUS$142.7bUS$9.0b34.2x55.9x3.5x
Sun, 13 Apr 2025US$514.0bUS$142.6bUS$10.0b34.6x51.6x3.6x
Tue, 11 Mar 2025US$611.4bUS$143.1bUS$9.8b43x62.7x4.3x
Thu, 06 Feb 2025US$673.0bUS$143.1bUS$10.4b39.5x64.7x4.7x
Sat, 04 Jan 2025US$651.8bUS$142.4bUS$10.2b43.1x63.9x4.6x
Mon, 02 Dec 2024US$672.6bUS$142.4bUS$10.2b44.5x65.7x4.7x
Wed, 30 Oct 2024US$677.0bUS$142.0bUS$8.3b36.9x81.9x4.8x
Fri, 27 Sep 2024US$727.0bUS$141.8bUS$8.5b38x85.5x5.1x
Sun, 25 Aug 2024US$743.2bUS$141.8bUS$8.5b37.4x87.8x5.2x
Tue, 23 Jul 2024US$675.6bUS$141.2bUS$12.2b40.7x55.3x4.8x
Thu, 20 Jun 2024US$696.9bUS$141.3bUS$12.2b38.6x57.2x4.9x
Sat, 18 May 2024US$742.9bUS$141.5bUS$12.5b38.3x59.4x5.3x
Mon, 15 Apr 2024US$711.1bUS$142.0bUS$12.8b42.3x55.6x5x
Wed, 13 Mar 2024US$753.3bUS$142.1bUS$12.9b44.6x58.5x5.3x
Fri, 09 Feb 2024US$709.3bUS$141.9bUS$12.8b39.1x55.6x5x
Sun, 07 Jan 2024US$684.7bUS$153.9bUS$14.2b36.1x48.3x4.5x
Tue, 05 Dec 2023US$651.8bUS$153.7bUS$14.0b35.4x46.5x4.2x
Thu, 02 Nov 2023US$572.3bUS$153.9bUS$11.1b29.2x51.3x3.7x
Sat, 30 Sep 2023US$670.3bUS$154.6bUS$11.2b33.3x59.8x4.3x
Mon, 28 Aug 2023US$712.7bUS$154.6bUS$11.2b32.9x63.6x4.6x
Wed, 26 Jul 2023US$744.0bUS$155.0bUS$12.1b29.8x61.3x4.8x
Fri, 23 Jun 2023US$691.0bUS$152.4bUS$12.5b29.2x55.3x4.5x
Sun, 21 May 2023US$683.1bUS$152.1bUS$12.5b29x54.8x4.5x
Tue, 18 Apr 2023US$742.1bUS$154.6bUS$10.8b30.5x68.7x4.8x
Thu, 16 Mar 2023US$701.1bUS$154.5bUS$10.9b30x64.6x4.5x
Sat, 11 Feb 2023US$745.6bUS$155.6bUS$8.9b30.6x84.1x4.8x
Mon, 09 Jan 2023US$705.6bUS$155.2bUS$8.8b27.6x80.4x4.5x
Wed, 07 Dec 2022US$755.0bUS$155.1bUS$8.8b28x86.1x4.9x
Fri, 04 Nov 2022US$699.1bUS$154.7bUS$13.0b26.2x53.8x4.5x
Sun, 02 Oct 2022US$700.3bUS$152.2bUS$17.3b23.2x40.5x4.6x
Price to Earnings Ratio

40.5x


Total Market Cap: US$700.3bTotal Earnings: US$17.3bTotal Revenue: US$152.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Clinical Research and Equipment Industry Price to Earnings3Y Average 61.8x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 39.1x which is lower than its 3-year average PE of 61.8x.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 5.6% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does U.S. Clinical Research and Equipment compare with similar industries?

US Market0.26%
Healthcare-0.038%
Life Sciences-2.20%
Clinical Research and Equipment-2.20%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RGEN RepligenUS$124.514.3%
+US$288.0m		-10.8%PS10.4x
WST West Pharmaceutical ServicesUS$259.941.3%
+US$237.3m		-14.3%PE38.3x
QSI Quantum-SiUS$1.6127.8%
+US$70.9m		79.1%PS95.6x
TKNO Alpha TeknovaUS$5.6728.9%
+US$68.0m		30.0%PS7.8x
ABCL AbCellera BiologicsUS$4.774.4%
+US$59.8m		95.5%PS43.4x

Latest News

TKNO
US$5.67
Alpha Teknova
7D
28.9%
1Y
30.0%

Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce

Sep 25
Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce
DHR
US$185.91
Danaher
7D
-3.6%
1Y
-30.6%
TMO
US$468.00
Thermo Fisher Scientific
7D
-1.0%
1Y
-22.0%
ILMN
US$94.41
Illumina
7D
-6.4%
1Y
-25.2%
TEM
US$79.23
Tempus AI
7D
-8.4%
1Y
61.2%
A
US$124.38
Agilent Technologies
7D
-1.8%
1Y
-10.8%
WAT
US$292.65
Waters
7D
-3.6%
1Y
-13.9%

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Sep 19
Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)
PSNL
US$6.06
Personalis
7D
5.8%
1Y
30.0%

Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%

Sep 16
Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
RGEN
US$124.51
Repligen
7D
4.3%
1Y
-10.8%
WST
US$259.94
West Pharmaceutical Services
7D
1.3%
1Y
-14.3%
ABCL
US$4.77
AbCellera Biologics
7D
4.4%
1Y
95.5%
IQV
US$181.24
IQVIA Holdings
7D
-2.9%
1Y
-21.8%

NVIDIA Partnership And AI Analytics Will Reshape Life Sciences

Analysts have modestly raised IQVIA’s price target to $215.89, citing strong B2B metrics, business diversification, and resilience in core segments despite sector headwinds and macroeconomic uncertainty. Analyst Commentary Bullish analysts cite IQVIA’s stronger business-to-business metrics, workforce stability, and lower customer concentration as reasons for outperformance and insulation against pharma sector restructurings, supporting higher valuation multiples.
MTD
US$1,242.28
Mettler-Toledo International
7D
-2.5%
1Y
-12.5%

Pharmaceutical And Food Production Expansions Will Unlock Future Opportunities

The consensus Analyst Price Target for Mettler-Toledo International saw a marginal upward revision from $1,276 to $1,295, as key valuation metrics such as Future P/E and Discount Rate remained essentially unchanged. What's in the News Repurchased 197,053 shares (0.95%) for $218.74 million between April and June 2025; total buyback now 17,527,389 shares (64.7%) for $9,152.11 million under program initiated in 2010.
CYRX
US$9.56
Cryoport
7D
7.8%
1Y
20.6%

Cold Chain Expansion Will Support Cell And Gene Therapies

Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.
ATLN
US$4.20
Atlantic International
7D
22.8%
1Y
-30.0%

Atlantic International's Position Is Risky, It Is Not An Opportunity

Aug 01
QSI
US$1.61
Quantum-Si
7D
27.8%
1Y
79.1%

Quantum-Si Stock: A Small Position Is Warranted (Technical Analysis)

Jul 23